Pharmaceutical composition in form of hard peroral drug for treatment of gastrointestinal tract diseases
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of pharmaceutical composition in form of hard peroral drug form for treatment of gastrointestinal tract diseases. Pharmaceutical composition contains the following ingredients: trimebutin maleate, lactose, colloidal silicon dioxide, talc, corn starch, magnesium stearate.
EFFECT: obtained pharmaceutical composition ensures high clinical effect.
5 cl, 2 ex, 1 tbl
The invention relates to pharmaceutical industry and medicine, in particular to pharmaceutical compositions for the treatment of diseases of the gastrointestinal tract (GIT).
For already quite a long period of time all over the world there is a steady trend of increasing prevalence of diseases of the digestive tract. Today, every tenth inhabitant of Russia suffers from any disease of the digestive system. This is due to the acceleration of the rhythm of life, the deterioration of the ecological environment, increased stress, deterioration and the emergence of new food products.
In addition, the cause of such conditions often lies in the fact that they take place against the background of other diseases such as tonsillitis, vegetative-vascular dystonia, astheno-neurotic syndrome, etc. Or Vice versa, the cause of chronic diseases of various organs can be a pathology in the intestine. For example, prolonged Candida in gynaecology, untreatable and turning into a chronic infection in urology, dermato-venereology, cosmetology are often unrecognized consequence of diseases of the digestive system.
Functional bowel diseases include disorders of his motor and transport (absorption and secret) functions without irreversible structural changes. IP is olzoeva drug therapy depends on the type of functional disorders. Medical therapy of diseases of the digestive tract, accompanied by a weakening of the tone and peristalsis of the different sections of the gastrointestinal tract (gastroesophageal reflux disease and reflexitivity, replicaomega and dyskinetic variants of functional dyspepsia, hipopotamo dyskinesia duodenum and biliary tract, hipopotamo variant of irritable bowel syndrome and others), includes the use of drugs that increase the motility of the digestive tract.
Medicines be given with this purpose (these drugs is called "prokinetic"), exert their effects either through stimulation of cholinoreceptors (karbaholina inhibitors holinesterzy), or by blocking dopamine receptors.
One of the first drugs used as prokinetic is metoclopramide, important characteristics of which are the ability to improve the tone of the lower esophageal sphincter with simultaneous relaxation of the pyloric sphincter and the duodenal bulb, increased peristalsis and accelerate gastric emptying. Most side effects are expressed in metoclopramide that is associated with the passage of the drug through the blood-brain barrier. When receiving metoclopramide they occur in 5-30% of patients (Grigoriev SURDS Prokinetics funds. In the book: Features of pharmacotherapy in pediatric gastroenterology. Edited Ameproof. M, 1998).
Similar mechanism of action to metoclopramide, but it is more effective domperidone. The drug blocks the D2-dopamine receptors, thereby increasing the tone of the lower esophageal sphincter, increasing the motor-evacuation function of the esophagus and stomach, exerting a positive influence on esophageal clearance. Simultaneously domperidone relieves vomiting, nausea and hiccups. Quickly and adequately absorbed in the digestive tract.
Much less common side effects observed in the appointment of domperidone 0.5 to 1.8 percent (Bagnenko SF, Y.V. Nazarov, M. Kabanov Methods pharmacological correction of motor-evacuation disorders of the stomach and duodenum. Roused. log. Diseases of the digestive system. 2004; 1: 19-23.).
Various undesirable effects described in patients taking loperamide. This information is based not only on data of domestic and foreign researchers (the performance took place AA diarrhea Syndrome and the possibility of application of different forms of Imodium in its treatment. Rusmedcom. Diseases of the digestive system. 2001; 2: 46-50).
The universal regulators of motility of the digestive tract is trimebutine. Physiological effects associated with exposure to enkephalinase Rotz the Torah (µ, d and C) of the stomach and intestines. Trimebutine characteristic of the modulating effect depending on the source level, it has a stimulating or relaxing effect on the digestive tract. Only a few cases of allergic skin manifestations found when using trimebutina.
Currently, there are a sufficient number of compositions for the treatment of gastrointestinal diseases, including those containing as the active component of trimebutine maleate (see, for example JP 3275622, KR 20040000928, CN 1839816, US 2003119903, WO 96/23493, EP No. 0806949). These listed drugs can be attributed to the equivalents of the claimed invention, of which the closest to the technical essence is described in the patent EP No. 0942718.
Object of the present invention is to provide pharmaceutical compositions containing trimebutine maleate in solid oral dosage form, more economical in the technology of preserving all the pharmacokinetic properties of the active substance is suitable for use in any conditions.
The technical result of the invention is the stability during storage, good raspadaemost, high clinical effect and high bioavailability of its components.
The problem is solved in that the claimed pharmaceutical composition for the treatment of diseases of jeludochno-intestinal tract contains the active ingredient trimebutine maleate and excipients: lactose, colloidal silicon dioxide, talc, corn starch, magnesium stearate, in the following ratio of ingredients, % by weight of active ingredient:
|Colloidal silicon dioxide||1,70-12,90|
The pharmaceutical composition may be in the form of solid dosage forms in the form of coated tablets.
The pharmaceutical composition contains a shell in an amount up to 5% by weight of the uncoated tablets.
The pharmaceutical composition as the shell contains polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide, acceptable dyes or ready-mix brand "Opadry II".
The tool get in a known manner to obtain tablets, established in pharmaceutical practice (Technology of medicinal forms / edited by Ivanova L.A. - M.: Medicine, 1991, vol. 2, p.142).
Izaberete the s can be illustrated by the following examples.
Composition per tablet, mg.
|Colloidal silicon dioxide||7|
Conformity assessment requirements Gosfarmakapei.
Analytical methods for evaluating the quality of the preparation was carried out on some key indicators, usually described the Fund: the appearance, the authenticity, the average weight of the tablets and the deviation in the mass, raspadaemost, impurities, assay, uniformity of dosage.
Tablets of white color face with embossed symbol on one side, representing two letters TM, above and below which are in line three triangles (for dosage 100 mg).
White pill round, biconvex with a stamped symbol on one side in the form of two pear-shaped elements and a scratch on the other side (for dosiro the Ki 200 mg).
The retention times of the peaks of maleic acid and trimebutine on the chromatogram of the test solution correspond to the retention times of the peaks of maleic acid and trimebutine on the chromatogram of the solution FROM trimebutine maleate, prepared for the "quantification".
C) the average weight of the tablets and the deviation in mass
In accordance with the requirements of the global Fund XI, issue 2, s.
(0,230 g+7,5%) for the dosage of 100 mg;
(0,280 g+7,5%) for dosage 200 mg
The determination is carried out in accordance with the requirements of the CFC 42-0003-04, using the device type Blade mixer". Wednesday - OD M solution of hydrochloric acid, the volume of medium dilution to 1000 ml, the mixer rotation speed is 100 rpm, the time of dissolution - 45 minutes
In a vessel put 1 tablet. After 45 min after the start of dissolution take 25 ml of the sample and filtered through a paper filter, 10 ml of the filtrate for dosage 100 mg or 5 ml of the filtrate to a dosage of 200 mg is placed in a volumetric flask with a capacity of 50 ml, bring the volume of solution, ML M solution of hydrochloric acid up to the mark and mix.
Measure the optical density of the resulting solution in the spectrophotometer at the maximum absorption at 268 nm in a cell with a layer thickness of 10 mm Parallel to measure the optical density of the solution WITH trimebutine maleate.
As the solution is even used OD M solution of hydrochloric acid. In the solution after 45 min becomes not less than 70% (Q) C22H29NO5·4H4O4(trimebutine maleate).
The determination is performed by HPLC simultaneously with quantification. The chromatogram of the test solution are recorded within 2 times the retention time of the peak of trimebutine.
The content of a single impurity in the product is not more than 1.5%.
The total content of impurities in the drug no more than 2.5%.
E. Quantitative determination
About 0.12 g (for dosage 100 mg), or 0,073 g (for dosage of 200 mg (accurately weighed) of the powder of crushed tablets are placed in a volumetric flask with a capacity of 50 ml, add 30 ml of a mixture of 0.01 M solution of hydrochloric acid and acetonitrile (13:7), shake for 10 minutes, bring the volume of solution of the same mixture to the mark, mixed and filtered through a nylon filter membrane with a pore size of 0.45 μm or centrifuged at 7000 rpm for 5 minutes.
5 ml of the resulting solution is placed in a volumetric flask with a capacity of 25 ml, the volume was adjusted solution of the same mixture to the mark and mix (test solution).
Consistently chromatographic solution WITH trimebutine maleate and the test solution.
The content of trimebutine maleate is 0,095 to 0,105 g, considering the average weight of one tablet for dosage 100 mg
The content of trimebutine maleate is 0,190 to 0,210 g, considering the average weight of one tablet for dosage 200 mg
The proposed combination of the active principle and excipients was determined experimentally and is the best.
The result is a mixture of substances with good processing properties in the process of granulation and tableting, and the resulting tablets have properties that satisfy the requirements of the pharmaceutical agent, i.e. they are in a saleable condition without chips and cracks, have sufficient strength and raspadaemost, are stored for at least 2 years, we provide high clinical effect, convenient dosage and high bioavailability of incoming components and are economically feasible.
1. Pharmaceutical composition for the treatment of diseases of the gastrointestinal tract, comprising as an active ingredient of trimebutine maleate and excipients, characterized in that it contains excipients: lactose, colloidal silicon dioxide, talc, corn starch, magnesium stearate in the following ratio of ingredients, % by weight of active ingredient:
|Trimebutine maleate||61,0 is 71.5||Lactose||12,9-of 37.8|
|Colloidal silicon dioxide||1,7-12,9|
2. The pharmaceutical composition according to claim 1, characterized in that it is made in the form of solid dosage forms.
3. The pharmaceutical composition according to claim 2, characterized in that it is made in the form of coated tablets.
4. The pharmaceutical composition according to claim 3, characterized in that the shell is up to 5% by weight of the uncoated tablets.
5. The pharmaceutical composition according to claim 4, characterized in that the shell contains polyvinyl alcohol, talc, polyethylene glycol, titanium dioxide, acceptable dyes or ready-mix brand "Opadry II".
SUBSTANCE: invention relates to medicine and deals with nanoliposome which includes liposomal membrane, contains ethgerificated lecitin and one or more physiologically active ingredients, incorporated in the internal space of liposomal membrane, method of obtaining such, as well as composition for prevention or treatment of skin diseases, containing nanoliposome.
EFFECT: invention ensures long-term stability and homogenecity of nanoliposomes.
15 cl, 22 ex, 4 dwg, 2 tbl
SUBSTANCE: group of inventions relates to medicine, namely to dentistry, and deals with medications for restoration of periodontal tissues and methods of their obtaining. Biotransplant for treatment of periodontal diseases represents suspension which contains cultures of autological or allogenic fibroblasts, or fibroblast-like cells in 0.9% solution of sodium chloride in concentration 2.0-10.0x106 in 1 ml of biotransplant, integrated on pharmaceutically acceptable biocompatible biodegradable carrier, selected from the group: acellular matrix, hyaluronic acid preparation, acellular matrix and hyaluronic acid preparation, with specified volume ratio of cell culture suspension ands carrier, which makes it possible to obtain consistence convenient for injecting and, together with expressed clinical effect ensures low traumaticity and simplicity of injecting. Preferable, as carrier, used is crushed to size 100-200 mcm acellular matrix "Saimetra". Also claimed is method of treating periodontal diseases, which lies in the following: on mucous membrane of gum in region of defect one week before biotransplant introduction preliminarily made are cuts provoking an acute inflammatory process resulting in increase of tissue volume, which makes it possible to carry out lossless introduction of large volume of biotransplant. After that, into defect area by means of injection two times with interval 1-4 weeks introduced is claimed biotransplant, using 3.6-60×106 cells per treatment course, which ensures optimal time interval for cell engraftment and restoration of periodontal tissues.
EFFECT: increase of treatment efficiency.
7 cl, 3 ex, 2 dwg
SUBSTANCE: composition for preventive and/or therapeutic treatment of respiratory pathologies and/or infections, or influenza, or for simultaneous improvement and/or regulation of organism's intestine function, includes mixture of bacterial strains, selected from: Bifidobacterium lactis LMG P-21384, Lactobacillus casei subspecies rhamnosus DSM 16605, Lactobacillus plantarum LMG P-21021 or Lactobacillus plantarum, LMG P-21020 or Lactobacillus plantarum LMG P-21022 or5 Lactobacillus plantarum LMG P-21023. Composition is applied for manufacturing medication for preventive and/or therapeutic treatment of respiratory pathologies and/or infections or for simultaneous improvement and/or regulation of organism's intestine function. Set for peroral introduction includes, at least, one composition of probiotic strains, at least one, pharmacologically active substance packed separately for introduction of said components.
EFFECT: efficiency of increasing systemic immune protection and immunity of mucous respiratory system membranes, improves or regulates organism's intestine function.
SUBSTANCE: invention relates to compounds of formula (I): where: A is a monocyclic or polycyclic aryl or heteroaryl group, where the heteroaryl radical denotes a 5-10-member cyclic system containing at least one heteroaromatic ring and containing at least one heteroatom selected from O, S and N; optionally substituted with one or more substitutes independently selected from a group comprising halogen atoms, C1-4alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C1-4alkoxy and a hydroxyl group; B is a monocyclic nitrogen-containing heteroaryl group, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from S and N; optionally substituted with one or more substitutes selected from a group consisting of halogen atoms, C1-4alkyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, aryl and C1-8alkylthio; either a) R1 is a group of formula: -L-(CR'R")n-G, where L is a binding group selected from a group consisting of a direct bond, -(CO)-, -(CO)NR'- and -SO2-; R' and R" is independently selected from hydrogen atoms; n assumes values from 0 to 1; and G is selected from a group consisting of a hydrogen atom and C1-4alkyl, aryl, heteroaryl, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from O, S and N; C3-8cycloalkyl and saturated heterocyclic groups, where heterocyclic group denotes a non-aromatic saturated 6-member carbocyclic ring in which one or two carbon atoms are substituted with a N heteroatom; where alkyl, C3-8cycloalkyl, aryl or heteroaryl groups are unsubstituted or substituted with one or more substitutes selected from halogen atoms; and R2 is a group selected from hydrogen atoms, halogen atoms and C1-4alkyl, C2-5alkynyl, C1-4alkoxy, -NH2 and cyano groups, where alkyl and alkynyl groups may be unsubstituted or substituted with one aryl group; or b) R2, R1 and -NH- group to which R1 is bonded form a group selected from groups of formulae and , where: Ra is selected from a hydrogen atom or groups selected from C1-4alkyl, C3-8cycloalkyl, aryl, aryl-C1-4alkyl, heteroaryl, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from O and N; saturated heterocyclic rings, where the heterocyclic group denotes a non-aromatic saturated 6-member carbocyclic ring in which one carbon atom is substituted with a heteroatom selected from O and N; and C1-4alkylthio; where the aryl or heteroaryl groups are unsubstituted or substituted with one or more groups selected from halogen atoms, cyano group, trifluoromethoxy and carbamoyl; Rb denotes hydrogen; and pharmaceutically acceptable salts thereof and N-oxides; provided that the compound is not selected from N-[6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]benzamide, N-[3-ethoxycarbonyl-6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]benzamide, and N-[3-ethoxycarbonyl-6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]formamide. The invention also relates to a pharmaceutical composition, use of compounds in any of claims 1-20, a method of treating a subject, as well as a composite product.
EFFECT: obtaining novel biologically active compounds having adenosine A2B receptor antagonist activity.
27 cl, 160 ex, 2 tbl
SUBSTANCE: invention relates to medicine, namely to vertebrology, and can be applied for treatment of intervertebral disk hernia. For this purpose treatment is carried out in, at least, two stages. At the first stage carried out is, at least, one course of complex therapy, directed at maximal softening of disk hernia, at suppression of inflammatory response and reduction of pain syndrome. At the second stage carried out is, at least, one session of focused extracorporal shock-wave therapy, directed at the area of pathological focus of intervertebral disk.
EFFECT: method insures high efficiency, even in conditions of ambulatory treatment of patients, in absence of scar changes or other treatment complications.
12 cl, 5 ex, 1 tbl
SUBSTANCE: invention relates to medicine, namely to surgery, and deals with treatment of purulent arthritis. For this purpose carried out is intra-joint introduction of not less than 10 ml of anolyte 0.3% NaCl with neutral Ph 7.3-7.7 and AFP +700-1100 mV. Said anolyte is introduced also peraorticularly in volume not less than 3 ml. Treatment course constitutes not less than nine days.
EFFECT: method increases treatment efficiency, including on the background of post-traumatic hemarthrosis, synovitis, in absence of toxic action on joint and on surrounding it tissues and without application of pharmaco- and physiotherapy.
SUBSTANCE: invention relates to medicine, namely to surgery, and deals with treatment of purulent arthritis. For this purpose carried out is intro-joint introduction of not less than 10ml of anolyte 0.3% NaCl with neutral Ph 7.3-7.7 and AFP +700-1100 mV. Said anolyte is introduced also paraorticularly in volume not less than 3 ml. Additionally perorally introduced is catholyte 0.3% NaCL with Ph 8.2-9.5 and AFP minus 450-600 mV. Catholyte introduction is carried out 3 times per day before meal in volume not less than 100 ml per intake. Treatment course constitutes not fewer than nine days.
EFFECT: method increases treatment efficiency, including at the background of post-traumatic hemarthrosis, synovitis, in absence of toxic action on joint and on surrounding it tissues and without application of pharmaco- and physiotherapy.
SUBSTANCE: invention relates to medicine, in particular to orthopedics, and deals with treatment of dynamic equino-plano-valgus deformation of foot in children with infantile cerebral paralysis. For this purpose, if associated pathological motor stereotype of hip and shin muscles is detected carried out are injections of Disport medication, both into triceps muscle of shin, and into thigh adductors, shin flexors and peroneal muscles. Total medication dose constitutes 30 units per weight kilogram, but not more than 1000 units. 50% of dose are introduced in triceps muscle of shin, by 20% of dose - into thigh adductors and shin flexors and 10% - in peroneal muscles. Repeated injections are carried out according to the same scheme after 4-6 months.
EFFECT: method insures efficient treatment due to direct reduction of hypertone of muscles, which cause foot deformation, reduction of tibial synkinesis, which is basic mechanism of deformation pathogenesis, as well as evening-out of pathological pose, which assists progression of pathological foot setting.
SUBSTANCE: invention relates to medicine, in particular to dentistry, and can be applied for treatment of "dry socket", which is formed after complicated tooth extraction. Method includes filling socket with blood clot. Clot is formed by intake from patient's vein of blood in quantity 15-25 ml with following centrifugation at rate 10-12 thousand turn/min for 5-7 minutes and addition in it after that of hydroxiapole - "ГАП-45" and 0.5 g of metrogyl. After introduction of blood clot into socket, from above additionally applied is membrane "TahoComb" in such a way, that it totally closes socket edges and is tightly fixed to clot and gum edges.
EFFECT: method makes it possible to reduce treatment terms and maximally reduce development of complication in treatment of said category of patients without carrying out additional medical manipulations.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to crystalline tiotropium bromide anhydrate differing in X-ray diffraction values by the presence of an orthorhombic elementary cell with the parameters a=11.7420 (4) Å, b=17.7960 (7) Å, c=19.6280 (11) Å and the cell volume V=4101.5 (3) Å.
EFFECT: invention refers to method for preparing said form of tiotropium bromide and to a based pharmaceutical composition for treating respiratory diseases, first of all for treating chronic obstructive pulmonary disease and asthma.
5 cl, 15 dwg, 18 tbl, 15 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and consists in development of a new dosage of the preparation 6-methyl-2-ethyl-3-hydroxypyridine succinate providing modified release of an active substance. A unit dosage form contains 6-methyl-2-ethyl-3-hydroxypyridine succinate in amount 30.0-70.0 wt %, as a release modifier - cellulose derivatives and/or polyacrylic resins in amount 1.0-20.0 wt %, as an excipient - microcrystalline cellulose in amount 20.0-50.0 wt % and lubricants. The unit dosage form represents a tablet or a capsule consisting of a variety of small dense spheroids containing 6-methyl-2-ethyl-3-hydroxypyridine succinate as a major component. A combination of matrix and instant, coated and uncoated spheroids enables preparation of a drug in the various dosage forms with controlled release rate.
EFFECT: invention allows to produce the unit dosage forms of the preparation 6-methyl-2-ethyl-3-hydroxypyridine succinate for certain treatment regimens of various diseases.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry and solid dosage form of calcium atorvastatin. Solid dosage form consists of core containing the following components, wt %: calcium atorvastatin - 1.5-25; microcrystalline cellulose - 2-30; calcium carbonate - 5-30; croscarmellose sodium - 0.5-5; stearic acid and/or its salt - 0.5-1.04; lactose "Lactopress Spraydry" - balance; and shell containing the following components, wt %: polyethylene glycol - 6-28; titanium dioxide - 10-35; talc - 5-25; silicon emulsion - 0.05-4; dye - 0-3; polyvinyl alcohol - balance.
EFFECT: invention provides for production of calcium atorvastatin pills satisfying requirements of National pharmacopeia XI.
4 cl, 5 tbl
SUBSTANCE: invention concerns a solid oral dosage form composition containing therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt in amount exceeding 46 wt %. The oral dosage form represents a tablet or a film-coated tablet. Aliskiren tablet is made by wet granulation with using mixed organic solvents or organic binding solutions.
EFFECT: elimination of aqueous granulation provides high stability of the dosage form of aliskiren and prolonged shelf-life.
18 cl, 2 ex
FIELD: food industry.
SUBSTANCE: present invention relates to gastral retentive composition containing active agent granulated together with the mixture of the first and the second gelatinating agents and mentioned composition production method the first gelatinating agent is a mixture of microcrystalline cellulose and sodium-carboxymethyl cellulose the second gelatinating agent is a compound with viscosity of 1% water solution which makes at least 600 centipoise at 25°C active agent is chosen from antibacterial compounds such as fluoroquinolones, antidiabetic compounds and antihypertensive medicinal agents.
EFFECT: invention provides gastral retentive composition with sustained release effect, which stays in stomach; medical agent has maximal absorption with improved therapeutic action there.
24 cl, 2 ex
SUBSTANCE: invention relates to pharmaceutical dosed form, which contains pharmaceutically active substance, unstable in presence of acid, which includes central nucleus, containing active substance and loosening agent, swelling coating, surrounding central nucleus, and enterosoluble coating, surrounding swelling coating. Swelling coating includes prolamin, preferably, zein. Pharmaceutically active substance includes benzimidazole, selected from omeprazole, lansoprazole, rabeprazole and pantoprazole.
EFFECT: invention ensures fast release of pharmaceutically active substance in medium, which has pH value at least 5.
33 cl, 12 ex
SUBSTANCE: invention concerns a tablet containing fluvastatin with sodium carboxymethylcellulose of calcium in the form of raising agent. The fluvastatin tablet is characterised by time of disintegration from 10 to 30 minutes and good bioavailability equivalent to bioavailability of serially produced capsules, containing fluvastatin. Manufacturing of tablets does peroral application of fluvastatin economically more favourable and more convenient for patients.
EFFECT: rising of profitability and convenience of peroral fluvastatin application to patients.
12 cl, 7 dwg, 6 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns pharmaceutical chemistry, namely to the method of obtaining of a medical product with a covering from a Pioglitazone hydrochloride which can be used as a therapeutic agent for treatment of diabetes, lipidemias, and also can be an antihypertensive agent, an antiobesity agent, diuretic or an antithrombotic agent.
EFFECT: medical product covered with a hydrochloride pioglitazon, possesses larger stability of an agent at storage, and also improved properties, such as solubility of a Pioglitazone hydrochloride.
11 cl, 30 ex, 3 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention describes solid dispersed measured drug including a core with pharmacological agent dispersed in the first matrix for controlled liberation at relatively low speed; and coating covering the core and including the agent dispersed in the second matrix for controlled liberation at relatively high speed. The first matrix can be represented by cross-linked starch with high amylose content, and the second matrix can be represented by polyvinylacetate and polyvinylpyrrolidone mix. Solid measured drug is preferably a pill.
EFFECT: reduced administration frequency, relatively stable medicine concentration in organism for a given time period and reduced undesired side effect frequency and intensity due to reduction of high concentrations in plasma.
19 cl, 5 dwg, 4 tbl, 4 ex
SUBSTANCE: claimed composition contains core including Rabeprasol or pharmaceutically acceptable salt thereof as acid secretion inhibitor in stomach and basic compound, intermediate coat coating the core, and overcoat applied on intermediate layer and containing water insoluble polymer and enterosoluble polymer. Also described is method for production of composition containing said preparation.
EFFECT: composition of prolonged storage time providing effective concentration of Rabeprasol in blood for long period of time.
16 cl, 5 dwg, 14 ex
FIELD: chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to solid medicinal formulations covered by enterosoluble envelope. Enterosoluble envelope represents a polymeric derivative as conglomerate of hydroxypropylcellulose and acetatephthalatecellulose in the presence of wax and Tween. Envelope has 1-10 layers and its mass is 0.1-10% of the solid pharmaceutical composition mass in the definite ratio of component in envelope. Also, invention represents methods for coating a pharmaceutical composition by such enterosoluble envelope. Invention provides the required disintegration of envelope for capsules as a whole and expanding assortment of active components among medicinal agents useful for applying the claimed cover and with inclusion to this enumeration of thermolabile medicinal immunobiological preparations.
EFFECT: improved and valuable properties of envelope, improved coating method.
9 cl, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry and deals with sublingual coated tablet, method of its manufacturing. Tablet contains nucleus, which does not contain pharmaceutically active substance, and coating, containing at least one active substance, tablet disintegrate within 15 minutes, providing fast supply of opioid analgetic into blood stream.
EFFECT: claimed tablet has high efficiency in treatment of beyond-threshold cancer pains.
25 cl, 3 ex, 7 tbl, 1 dwg